Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Comerica Bank

Comerica Bank raised its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 175.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170,780 shares of the biopharmaceutical company's stock after buying an additional 108,686 shares during the quarter. Comerica Bank owned 0.10% of Insmed worth $11,791,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Insmed by 1.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after acquiring an additional 123,429 shares during the period. Capital International Investors boosted its stake in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company's stock, valued at $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 182,337 shares of company stock worth $14,284,557 over the last ninety days. Company insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Stifel Nicolaus lowered their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. UBS Group upped their target price on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and an average target price of $94.00.

Insmed Stock Down 2.7 %

Shares of NASDAQ:INSM traded down $1.81 during trading hours on Thursday, hitting $66.47. The company's stock had a trading volume of 1,606,214 shares, compared to its average volume of 2,315,775. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a market capitalization of $12.09 billion, a price-to-earnings ratio of -11.93 and a beta of 0.84. The firm's fifty day moving average price is $72.82 and its 200 day moving average price is $73.37.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the company earned ($1.06) earnings per share. As a group, research analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.